AUGUSTINA AGARUWA: Open Payments
NPI 1376119024 · CLINTON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$442 in 17 payments from 10 companies in 2025. Trend: 2023 $17 · 2024 $287 · 2025 $442
Food & beverage: $442
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 1 | $105 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
| ABBVIE INC. | 3 | $64 |
| Lundbeck LLC | 3 | $59 |
| Neurocrine BioSciences, Inc. | 2 | $53 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
Products named: Auvelity, VRAYLAR, INGREZZA, ABILIFY ASIMTUFII, ABILIFY MAINTENA, REXULTI, Qelbree, FANAPT.
Industry payments across MD — which companies pay providers there.
